Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Eicosatetraenoic acid.
A polyunsaturated omega-3 fatty acid that acts as a dual inhibitor of cyclooxygenase and lipoxygenase pathways to modulate systemic inflammation and support joint health.
5282831
248.36 g/mol
4.3
(4E,7E,10E,13E)-hexadeca-4,7,10,13-tetraenoic acid
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Eicosatetraenoic acid across standard consumer modalities.
High susceptibility to oxidative rancidity requires nitrogen flushing or airtight softgel encapsulation rather than standard two-piece dry powder shells.
The hydrophobic nature and distinct lipid odor profile necessitate advanced microencapsulation to prevent oil separation and sensory rejection in pectin bases.
Significant payload limitations and the liquid lipid state of the molecule make it difficult to achieve therapeutic dosing within a thin-film polymer matrix.
Ready to launch a product featuring Eicosatetraenoic acid? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Eicosatetraenoic acid extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Eicosatetraenoic acid payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation